Off-label use of dupilumab for the treatment of moderate to severe atopic dermatitis in children aged below 6 years of age: a case series.

Szczegóły
Pełny tekst

Tytuł:: Off-label use of dupilumab for the treatment of moderate to severe atopic dermatitis in children aged below 6 years of age: a case series.
Autorzy:: Da J; Department of, Dermatology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Ali K; Department of Dermatology, Affiliated Hangzhou First People's Hospital, Zhejiang Chinese Medical University, Hangzhou, China.
Lu K; Department of, Oncological Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Lou H; Department of Dermatology, Affiliated Hangzhou First People's Hospital, Zhejiang Chinese Medical University, Hangzhou, China.
Qiu Y; Department of Dermatology, Affiliated Hangzhou First People's Hospital, Zhejiang Chinese Medical University, Hangzhou, China.
Shan J; Department of Dermatology, Affiliated Hangzhou First People's Hospital, Zhejiang Chinese Medical University, Hangzhou, China.
Wu L; Department of, Dermatology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Źródło:: Clinical and experimental dermatology [Clin Exp Dermatol] 2022 Feb; Vol. 47 (2), pp. 423-425. Date of Electronic Publication: 2021 Oct 19.
Typ publikacji:: Case Reports; Letter
Język:: English
Imprint Name(s):: Publication: 2023- : Oxford : Oxford University Press
Original Publication: Oxford : Blackwell Scientific Publications.
MeSH Terms:: Off-Label Use*
Antibodies, Monoclonal, Humanized/*therapeutic use
Dermatitis, Atopic/*drug therapy
Interleukin-4 Receptor alpha Subunit/*antagonists & inhibitors
Child, Preschool ; Drug Therapy, Combination ; Female ; Histamine Antagonists/therapeutic use ; Humans ; Male
References:: Odhiambo JA, Williams HC, Clayton TO et al. Global variations in prevalence of eczema symptoms in children from ISAAC phase three. J Allergy Clin Immunol 2009; 124: 1251-8.e23.
Simpson EL, Paller AS, Siegfried EC et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol 2020; 156: 44-56.
Blauvelt A, de Bruin-Weller M, Gooderham M et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389: 2287-303.
Sastre J, Dávila I. Dupilumab: a new paradigm for the treatment of allergic diseases. J Investig Allergol Clin Immunol 2018; 28: 139-50.
Simpson EL, Bieber T, Guttman-Yassky E et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375: 2335-48.
Beck LA, Thaçi D, Hamilton JD et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014; 371: 130-9.
Substance Nomenclature:: 0 (Antibodies, Monoclonal, Humanized)
0 (Histamine Antagonists)
0 (Interleukin-4 Receptor alpha Subunit)
420K487FSG (dupilumab)
Entry Date(s):: Date Created: 20210905 Date Completed: 20220311 Latest Revision: 20220311
Update Code:: 20240105
DOI:: 10.1111/ced.14925
PMID:: 34482550
: Raport

Pełny tekst

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja